Several proinflammatory cytokines are known to be involved in the pathogenesis of IBD, including tumor necrosis factor α (TNF-α) as well as interleukins IL-6 and IL-17, and modifying their production has shown benefits for disease control [2,3]. Here, TNF is linked to irritable bowel syndrome.